
Otsuka
OTSKY | OTC
$38.98
+$0.41 (+1.06%)
At close: Nov 16, 2026, 3:59 PM ET
$39.00
+$0.02 (+0.05%)
After-hours:
Nov 16, 2026, 2:59 PM ET
Otsuka Company Profile
Company profile explainedCompany Profile
Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded on July 8, 2008 and is headquartered in Tokyo, Japan.
Key Executives
| Name | Position |
|---|---|
| Makoto Inoue | President, Chief Executive Officer & Representative Director |
| Yuko Makino | Chief Financial Officer & Executive Director |
| Chiaki Sakurai | Senior EVice President, Operating Officer & Dir. of Nutraceutical Bus., Global Strat. and Planning Headquarters |
| Keiso Yamasaki | Executive Vice President, Operating Officer & Director of Corporation Planning Dept., Bus. Insights and Analytics |
| Manabu Kawata | Executive Vice President & Operating Officer of Business Development Department |
| Masayuki Kobayashi | Executive Director |
| Noriko Tojo | Executive Director |
| Shuichi Takagi | Executive Director |
| Tomohiro Emura | Executive Vice President & Operating Officer of IR, Public Relations, and Sustainability Promotion |
| Yoshiro Matsuo | Executive Deputy President & Representative Director |
Otsuka

| Country | Japan |
| IPO Date | Aug 3, 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 37,758 |
| CEO | Makoto Inoue |
Contact Details
2-9 Kanda-Tsukasamachi Tokyo,
TKY 101-0048 Japan
Stock Details
| Ticker Symbol | OTSKY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 689164101 |
| ISIN Number | US6891641010 |
| SIC Code | n/a |
Recent News
- 2 months ago / reuters.comOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
- 2 months ago / businesswire.comOtsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
- 3 months ago / seekingalpha.comOtsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study Prepared Remarks Transcript
- 3 months ago / seekingalpha.comOtsuka Holdings Co., Ltd. (OTSKY) Q2 2026 Earnings Call Prepared Remarks Transcript
- 4 months ago / seekingalpha.comAristotle Global Equity Advisory Q2 2026 Portfolio Review
- 4 months ago / prnewswire.comOtsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
Add to Watchlist
Select watchlists to add or remove OTSKY